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Neuropathic syndromes which are evoked by lesions to the peripheral or central nervous system are extremely difficult to treat,
and available drugs rarely joint an antihyperalgesic with a neurorestorative effect. N-Palmitoylethanolamine (PEA) exerts anti-
nociceptive effects in several animalmodels and inhibits peripheral inflammation in rodents. Aimed to evaluate the antineuropathic
properties of PEA, a damage of the sciatic nerve was induced in mice by chronic constriction injury (CCI) and a subcutaneous
daily treatment with 30mg kg−1 PEA was performed. On the day 14, PEA prevented pain threshold alterations. Histological studies
highlighted that CCI induced oedema and an important infiltrate of CD86 positive cells in the sciatic nerve. Moreover, osmicated
preparations revealed a decrease in axon diameter and myelin thickness. Repeated treatments with PEA reduced the presence of
oedema andmacrophage infiltrate, and a significant highermyelin sheath, axonal diameter, and a number of fibers were observable.
In PPAR-𝛼 null mice PEA treatment failed to induce pain relief as well as to rescue the peripheral nerve from inflammation and
structural derangement. These results strongly suggest that PEA, via a PPAR-𝛼-mediated mechanism, can directly intervene in the
nervous tissue alterations responsible for pain, starting to prevent macrophage infiltration.
1. Introduction
Neuropathic painmay originate from several different causes.
Mechanical peripheral neuropathies are the consequence of
local or extrinsic compression phenomena or impingement
by an anatomic neighbor causing a localized entrapment.
Traumatic neuropathies are the result of either closed injuries
or open injuries to peripheral nerves [1, 2]. Both of these
categories are characterized by an important inflammatory
component that plays a central role in the pathogenesis of
neuropathic pain. Inflammatory cells (e.g.,macrophages), the
production of molecules that mediate inflammation (cyto-
kines), and the production of nervous growth factors are
involved [3, 4]. In animal models it has been demonstrated
that peripheral nerve injuries induce a profound local inflam-
matory response that involves T cells andmacrophages [5]. In
particular, in the neuropathic painmodel induced by chronic
constriction injury (CCI) an important macrophage infiltrate
has been described in the damaged sciatic nerve [5–7] and
in the dorsal root ganglia [8, 9]. The inflammatory response
paralleled with nervous tissue alterations and pain [7, 10].
N-Palmitoylethanolamine (PEA), the endogenous amide
between palmitic acid and ethanolamine, belongs to the fam-
ily of fatty acid ethanolamides (FAEs), a class of lipid medi-
ators. PEA exerts antinociceptive effects in several animal
models [11, 12], prevents neurotoxicity and neurodegenera-
tion [13, 14], and inhibits peripheral inflammation and mast
cell degranulation [15]. Endogenous and exogenous PEA can
modulate macrophage response [16, 17].
Anti-inflammatory effects of PEA have been associated
with peroxisome proliferator-activated receptor-(PPAR-)𝛼
activation [18], a nuclear receptor fundamental in the control
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of inflammatory responses, and expressed in various cells
of the immune system [19, 20]. PEA does not elicit anti-
inflammatory effects in mutant PPAR-𝛼 null mice (PPAR-
𝛼
−/−). Indeed, when assessed in either the carrageen hindpaw
or phorbol ester ear pinna tests, PEA reduced inflammation
in wild-type, but not in PPAR-𝛼−/−, mice [18]. On the other
hand, LoVerme and collegues [12] demonstrated the pivotal
role of PPAR-𝛼 in the PEA pharmacodynamic mechanism to
relieve pain.
In a mouse peripheral neuropathy model (CCI) we eval-
uated the effects of repeated PEA treatments on the sciatic
nerve lesions responsible for neuropathic pain. Aimed to
highlight the role of PPAR-𝛼 in PEA-evoked neurorestoration
during neuropathy, a morphological study has been perfor-
med in both wild-type and PPAR-𝛼 null mice.
2. Materials and Methods
2.1. Animals. All procedures met the European guidelines
for the care and use of laboratory animals (86/609/ECC
and 2010/63/UE), and those of the Italian Ministry of
Health (DL 116/92). Male wild-type (WT) and PPAR-
𝛼
−/− (KO) (B6.129S4-SvJae-Pparatm1Gonz) mice, previously
backcrossed to C57BL6 mice for 10 generations, were bred in
our animal facility, where a colony was established andmain-
tained by heterozygous crossing. Mice were genotyped as
described on the supplier webpage (http://jaxmice.jax.org/),
with minor modifications. DNA was extracted from tails
using the RedExtract kit (Sigma-Aldrich, Milan, Italy). All
animals were maintained on a 12 h light/12 h dark cycle with
free access to water and standard laboratory chow.
2.2. Chemicals. PEA was from Tocris (Bristol, UK); it was
dissolved in PEG andTween 80 2 : 1 (Sigma-Aldrich) and kept
overnight under gentle agitation with a microstirring bar.
Before injection, sterile saline was added so that the final
concentrations of PEG and Tween 80 were 20 and 10%
v/v, respectively. Drug was injected subcutaneously (s.c.) in
a dose of 30mg kg−1—0.3mL mouse—for consecutively 14
days from the day after surgery.
2.3. CCI Model. The sciatic nerve of 5-6-week-old WT and
KO mice were surgically ligated as described [21]. In brief,
the animals were anesthetized with ketamine (100mg kg−1
i.p) and xylazine (10mg kg−1 i.p.), the left thigh was shaved
and scrubbed with Betadine, and a small incision (2 cm in
length) was made in the middle of the left thigh to expose
the sciatic nerve.The nerve was loosely ligated at two distinct
sites (spaced at a 2mm interval) around the entire diameter
of the nerve using silk sutures (7-0). Behavioral tests were
performed on the day 14 after surgery.
2.4. Mechanical Hyperalgesia. We measured mechanical
hyperalgesia using a Randall-Selitto analgesimeter for mouse
(Ugo Basile, Varese, Italy). Latencies of paw withdrawal to a
calibrated pressure were assessed on ipsilateral (ligated) paws
on day 14 following ligatures. Cut-off force was set at 60 g.
2.5. Mechanical Allodynia. To assess for changes in sensation
or in the development of mechanical allodynia, sensitivity to
tactile stimulation was measured using the Dynamic Plan-
tar Aesthesiometer (DPA, Ugo Basile, Italy). Animals were
placed in a chamber with a mesh metal floor covered by
a plastic dome that enabled the animal to walk freely but
not to jump. The mechanical stimulus was then delivered
in the mid-plantar skin of the hind paw. The cutoff was
fixed at 5 g. Each paw was tested twice per session. This test
did not require any special pretraining, just an acclimation
period to the environment and testing procedure. Testing was
performed on ipsilateral (ligated) paw on day 14 after ligation.
Cutoff force was set at 5 g.
2.6. Tissue Explants. After the algesic test, animals were
sacrificed and the ipsilateral sciatic nerves, 1 cm proximal and
distal to the ligation, were explanted; the portion containing
the ligature was eliminated. Contralateral nerves were also
dissected, and an equivalent portion was collected. Spinal
cord was removed, and lumbar section was immediately
frozen in liquid nitrogen.
2.7. Osmic Acid Staining. The sciatic nerve was stored in a 4%
glutaraldehyde solution. The tissue samples were osmicated
in 1% solution of osmium tetroxide for 2 h under constant
agitation. Before and after osmication, the tissue was repeat-
edly rinsed in 0.1M sodium cacodylate at pH 7.4. After
gradual dehydration in ethanol, the osmicated nerve samples
were embedded in paraffin (Diapath,Milan, Italy). Transverse
5 𝜇m sections were cut on a Reichert microtome (Leica,
Rijswijk, The Netherlands), mounted with Canada balsam,
and observed under a light microscopy.
2.8. Azan-Mallory Stain. After the sacrifice, the sciatic nerve
was fixed in situ using 4% formalin in phosphate buffer (pH
7.4), nerves were fixed in 4% buffered neutral formalin solu-
tion, and then the nerve was embedded in paraffin. Finally
5 𝜇m sections were stained with Azan-Mallory for light
microscopy studies andwere graded for oedema and infiltrate
[22]. The sections were semiquantified by an arbitrary scale
starting from 1, mild infiltrate and oedema, up to 10, severe
infiltrate and widespread oedema.The procedure was carried
out by an independent researcher who was masked to the
experiment.
2.9. Morphometry. Morphometry was performed on cross
sections of osmium-fixed sciatic nerves 10mm starting from
the level of injury or at the corresponding level in uninjured
control nerves. The 10mm cross section corresponded to a
level distal or proximal to the injury. Counts and measure-
ments were carried out using ImageJ analysis software.
The first step of morphometric analysis of the sciatic
nerve consisted of identifying and capturing the entire fasci-
cle image, followed by measurement of the fascicle perimeter
and area by contouring its internal epineural (magnification:
objective 20x). The next step consisted of capturing sequen-
tial inner areas of the fascicle (magnification: objective 100x).
The high-magnificationmicrographs were randomly selected
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Figure 1: Chronic treatment effects on pain behaviour. Comparison of PEA-effects in PPAR-𝛼+/+ and −/− mice. (a) Response to a mechanical
noxious stimulus on the ipsilateral paw 14 days after CCI evaluated by Randall-Selitto test. (b) Response to amechanical nonnoxious stimulus
evaluated by Von Frey test. PEA (30mg kg−1) was daily s.c. administered for 14 days starting from the day of operation. Each value represents
the mean of 2 experiments with 12 mice per group. ∗∗𝑃 < 0.01 versus vehicle-treated mice.
in nonoverlapping areas to cover 50–75% of the total cross-
sectional area of the nerve. The random selected histological
images were converted into binary (black and white) images
and cleaned of any blood vessels, degenerated nerve fibers,
and artifacts, and the following parameters were then mea-
sured: total number and density of nerve fibers, axon dia-
meter, and myelin sheath area. The number of small fibers,
defined as fibers < 4 𝜇m, and large fibers, defined as fibers
≥ 4 𝜇m, was calculated, and the myelin thickness was deter-
mined from the difference in perimeter between the fiber and
the axon. The procedure was carried out by an independent
researcher who was masked to the experiment.
2.10. Immunohistochemistry. Sections of 5 𝜇m were deparaf-
finized, dehydrated, and submitted to antigen retrieval. Sec-
tions were then blocked by incubation with 3% normal goat
serum for 20min. Macrophages were detected using anti-
CD86 antibody. The slides were then incubated with the
primary antibodies for 18 h at 4∘C. After washing in TBS, the
sectionswere treatedwith the secondary antibody conjugated
to Alexa Fluor 488 (1 : 1000, Invitrogen, Milan, USA) for 1 h
at room temperature. Nuclei were counterstained with DAPI.
Quantitative analysis of CD86 positive cells was performed
collecting at least three independent fields through a 20 ×
0.5NA objective, and positive cells were counted using the
“cell counter” plugin of ImageJ.
2.11. Western Blot Analysis. The lumbar portion of the spinal
was homogenized in lysis buffer containing 50mM Tris-
HCl pH 8.0, 150mM NaCl, 1mM EDTA, 0.5% Triton X-100,
Complete Protease Inhibitor (Roche), and the homogenate
was incubated on ice for 30 minutes. Then, the suspension
was sonicated on ice using three 10-second bursts at high
intensity with a 10-second cooling period between each
burst. After centrifugation (13000 ×g for 15 minutes at 4∘C)
aliquots containing 20 𝜇g total protein underwent to western
blot analysis using a mouse anti-COX2 antiserum (1 : 1000;
Cell Signalling, USA). Densitometric analysis was performed
using the “ImageJ” analysis software, and results were nor-
malized to 𝛽-actin immunoreactivity (1 : 1000 rabbit anti-
serum, SantaCruz Biotechnology) as internal control.
2.12. Statistical Analysis. For behavioral experiments, results
were expressed as the mean ± SEM, and analyses were con-
ducted using Statistica (Statsoft, Tulsa, OK, USA).
Histological, morphometric, and immunohistochemical
analyses were performed on 5 mice per group, evaluating
6 sciatic nerve sections for each animal. Comparison, were
carried out using Mann-Whitney nonparametric tests. In all
cases, the investigator was blind to the experimental status
of each animal. Slides from control and experimental groups
were labeled with numbers so that the person performing
the image analysis was blinded as to the experimental group.
In addition, all images were captured and analyzed by an
investigator other than the one who performed measures to
avoid possible bias. Western blot analysis were performed
on 5 mice per group; comparisons were carried out using
Bonferroni posttest. Data were analyzed using the “Origin
7.5” software. Differences were considered significant if 𝑃 <
0.05 or otherwise differently reported.
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Figure 2: Morphometry: number of fibers. 5 𝜇m nerve sections of osmium-fixed tissues were analyzed. The distal and the proximal tract of
the ipsilateral ligated nerve (CCI) was compared with the contralateral and with the sciatic nerve of sham-operated animals (sham). Effect
of repeated PEA administrations (30mg kg−1 s.c. for 14 days) on the number of nervous fibers in respect to vehicle-treated CCI animals and
vehicle-treated sham animals. (a) PPAR-𝛼+/+ mice versus (b) knock-out animals. Quantitative analysis was performed evaluating 5 animals
for each group. ∗𝑃 < 0.05 was considered as significantly different from sham, vehicle-treated mice. ∘𝑃 < 0.05 was considered as significantly
different from CCI, vehicle-treated mice.
3. Results
PEA, (30mg kg−1) s.c. daily administered starting on the day
of operation, prevented pain threshold alterations elicited by
CCI (Figure 1). In wild-type animals 14 days after injury, PEA
reduced the hypersensitivity to a mechanical noxious stimu-
lus (Randall-Selitto test; Figure 1(a)) as well as the hypersen-
sitivity to a nonnoxious mechanical stimulus (Figure 1(b)).
PEA efficacy against CCI-evoked pain was lacked in PPAR-
𝛼 knock-out (−/−) mice (Figures 1(a) and 1(b)).
On the 14th day after injury, a morphological evaluation
of the sciatic nerves was performed both on the proximal
and distal parts from the ligation. 5 𝜇m sections of paraffin-
embedded nerve were stained by the Azan-Mallory pro-
cedure revealing that CCI was able to induce a stronger
alteration in the distal portion of the ipsilateral nerve. The
histological analysis highlighted an extensive demyelination,
myelin abnormalities like characteristic aggregate, generally
termed “ovoids”, pathognomonic of myelin degeneration
(Figure 7, arrows), and an axonal damage. As shown in
Figure 2 the number of fibers was significantly reduced,
particularly in the distal part of the nerve of both wild-type
(+/+; graph (a)) and PPAR-𝛼 null (−/−; graph (b)) animals.
Morphometric evaluation of osmium-fixed tissues
allowed the characterization of the alteration of the myelin
sheet thickness and axonal diameter, as well as the discrimi-
nation of large against small fibers (stratified by diameter
in >6𝜇m for large and <6𝜇m for small). CCI was able to
decrease the myelin thickness of large and small fibers in the
distal portion of the ipsilateral nerve in respect to the sham
both in wild-type and in knock-out mice (Figures 3(a) and
3(b), large fibers; Figures 3(c) and 3(d), small fibers).
In regard to axon diameter, a time-dependent decrease
was revealed for all the fibers, particularly the small type, both
in the distal and in the proximal portions of the ipsilateral
nerve; morphometry revealed a similar profile in PPAR-𝛼+/+
(Figures 4(a) and 4(c)) and PPAR-𝛼−/− (Figures 4(b) and
4(d)) animals. In wild-type mice repeated PEA administra-
tions, 30mg kg−1 for 14 days, were able to preserve the nerve
morphology. Nerve sections of PEA-treated mice showed a
higher number of fibers in respect to the saline-treated groups
(Figure 2(a)); the myelin thickness in the distal portions of
the nerve was decreased to a lesser extent (Figures 3(a) and
3(c)); the axon diameter was protected in the PEA group both
in the proximal and in the distal nerve parts, even in the small
fibers (Figures 4(a) and 4(c)). PEA was completely ineffective
in PPAR-𝛼 null mice in preventing sciatic nerve alterations
evaluated as number of fibers (Figure 2(b)), myelin thickness
(Figures 3(b) and 4(d)) and axon diameters (Figures 4(b) and
4(d)).
Azan-Mallory staining revealed an abundant inflamma-
tory infiltrate in the ligated nerve. Figure 5 shows the infiltrate
evaluation 14 days after ligation: inflammatory cells were
present in the proximal and, at higher level, in the distal
parts of both PPAR-𝛼+/+ (graph (a)) and PPAR-𝛼−/− (graph
(b)) mice. 30mg kg−1PEA significantly prevented the cellular
infiltrate number in wild-type (Figure 5(a)) but not in KO
animals (Figure 5(b)).
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Figure 3: Morphometry: myelin thickness. Nerve sections (5𝜇m) of osmium-fixed tissues were analyzed.The distal and the proximal tract of
the ipsilateral ligated nerve (CCI) was compared with the contralateral and with the sciatic nerve of sham-operated animals (sham). Myelin
thickness of large and small fibers of PEA-treated (30mg kg−1 s.c. for 14 days) PPAR-𝛼+/+ ((a) and (c)) and PPAR-𝛼−/− ((b) and (d)) mice
in respect to saline-treated CCI and saline-treated sham animals. Quantitative analysis was performed evaluating 5 animals for each group.
∗
𝑃 < 0.05 was considered as significantly different from sham, vehicle-treated mice. ∘𝑃 < 0.05 was considered as significantly different from
CCI, vehicle-treated mice.
Moreover, both osmium fixed and Azan-Mallory-stained
sections (Figure 7) allowed the observation of amassive pres-
ence of oedema among the fibers of CCI animals. Figure 6
show the quantitative oedema evaluation 14 days after oper-
ation: the alteration was more evident in the distal portion
than in the proximal one without revealable differences due
to knock down PPAR-𝛼 gene. PEA (30mg kg−1 s.c. for 14
days) was able to prevent the oedema induction of about 50%
in CCI wild-type mice (Figure 6(a)). No oedema protective
effects were observable in PEA-treated PPAR-𝛼−/− animals in
respect to vehicle (Figure 6(b)).
The immune inflammatory cells evaluated were dif-
fusely distributed throughout the nerve tissue in all samples
of the CCI mice, whereas a mild CD86 positive reaction
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Figure 4: Morphometry: axon diameters. Nerve sections (5𝜇m) of osmium-fixed tissues were analyzed. The distal and the proximal tract of
the ipsilateral ligated nerve (CCI) was compared with the contralateral and with the sciatic nerve of sham-operated animals (sham). Axon
diameters of large and small fibers of PEA-treated (30mg kg−1 s.c. for 14 days) wild-type ((a) and (c)) and PPAR-𝛼 null ((b) and (d)) mice
in respect to saline-treated CCI and saline-treated sham animals. Quantitative analysis was performed evaluating 5 animals for each group.
∗
𝑃 < 0.05 was considered as significantly different from sham, vehicle-treated mice. ∘𝑃 < 0.05 was considered as significantly different from
CCI, vehicle-treated mice.
was detectable in CCI mice administered with PEA as
well as in sham-operated animals. PPAR-𝛼−/− mice showed
a persistence of macrophage infiltrate also in the nerve of
PEA-treated animals (Figures 8 and 9).
CCI-dependent inflammatory response in the central
nervous system was evaluated measuring COX2 levels. As
shown in Figure 10, in wild-type mice PEA was able to sig-
nificantly prevent COX2 increase induced by nerve ligation.
This anti-inflammatory effect was lost in PPAR-𝛼−/− animals.
4. Discussion
Pharmacological treatment of peripheral neuropathy is actu-
ally restricted to symptomatic drugs that are only partially
able to control pain perception [23]. Antidepressants, antin-
covulsants, and opioids cannot intervene in nervous tissue
alterations that act as a base of neuropathic pain. The present
results describe the direct protective effect of repeated PEA
treatment on lesioned peripheral nerves.
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Figure 5: Infiltrate evaluation. On the 14th day after CCI, 5 𝜇mnerve sections of formalin-fixed tissues were analyzed by Azan-Mallory stain,
and the presence of inflammatory infiltrate was evaluated and quantified by an arbitrary scale starting from 1, mild infiltrate, up to 10, severe
infiltrate. Effect of PEA repeated treatments (30mg kg−1 s.c. daily) was observed in (a) PPAR-𝛼+/+ and in (b) −/− mice where the distal and
the proximal tract of the ipsilateral ligated nerve of CCI was compared with the contralateral and with the sciatic nerve of sham-operated
animals. Quantitative analysis was performed evaluating 5 animals for each group. ∗𝑃 < 0.05 was considered as significantly different from
sham, vehicle-treated mice. ∘𝑃 < 0.05 was considered as significantly different from CCI, vehicle-treated mice.
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Figure 6: Oedema evaluation. On the 14th day after CCI, 5 𝜇m nerve sections of formalin-fixed tissues were analyzed by Azan-Mallory stain
and the presence of oedema infiltrate was evaluated and quantified by an arbitrary scale starting from 1, mild oedema, up to 10, widespread
oedema. Effect of PEA repeated treatments (30mg kg−1 s.c. daily) was observed in (a) PPAR-𝛼+/+ and in (b) −/− mice where the distal and
proximal tract of the ipsilateral ligated nerve of CCI was compared with the contralateral and with the sciatic nerve of sham-operated animals.
Quantitative analysis was performed evaluating 5 animals for each group. ∗𝑃 < 0.05 was considered as significantly different from sham,
vehicle-treated mice. ∘𝑃 < 0.05 was considered as significantly different from CCI, vehicle-treated mice.
CCI induces morphometric alterations of the sciatic
nerve that dramatically affect the portion distal from the
injury and that are also able to induce severe proximal impair-
ment. At the same dose active in pain relief, PEA prevents
the reduction of myelin sheet thickness and axonal diameter
and improves a characteristic degeneration of myelin as
highlighted by Azan-Mallory staining. According to previous
results [7, 24, 25] CCI-mediated nerve architecture derange-
ment is accompanied by a profound local inflammatory reac-
tion which includes oedema, infiltration of hematogenous
immune cells, and induction of various soluble factors like
cytokines and chemokines. In particular, the present results
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Figure 7: Light micrographs from 5 𝜇m transverse sections of mouse sciatic nerve stained by Azan-Mallory, comparison between PPAR-𝛼+/+
and PPAR-𝛼−/− animals; 14th day. Sham: section of sciatic nerve from sham animals; CCI + vehicle: distal part of the sciatic nerve of injured
vehicle-treated animals; CCI + PEA distal part of the sciatic nerve of CCI mice s.c. treated with 30mg kg−1 PEA daily for 14 days starting
from the surgery. Ovoids are evidenced by arrows. Original magnification 20x.
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Figure 8: CD86 positive cells evaluation in sciatic nerve. 14 days after CCI, 5𝜇m sections of the formalin-fixed distal part of the sciatic nerve
underwent immunohistochemical staining for CD86. Effect of PEA repeated treatments (30mg kg−1 s.c. daily) was evaluated in (a) PPAR-
𝛼
+/+ and in (b) PPAR-𝛼−/− mice, and quantitative analysis was performed evaluating 5 animals for each group. ∗𝑃 < 0.05 was considered as
significantly different from sham, vehicle-treated mice. ∘𝑃 < 0.05 was considered as significantly different from CCI, vehicle-treated mice.
describe a characteristic infiltrate of CD86 positive cells.
CD86 is a phenotypic marker of the “classically activated”
M1 macrophages stimulated by proinflammatory cytokines,
as IFN𝛾, or by lipopolysaccharide and typically recruited after
nervous system trauma [26]. M1 macrophages produce high
levels of oxidative metabolites (e.g., nitric oxide and superox-
ide) and proinflammatory cytokines that are essential for host
defense and tumor cell killing but that also cause collateral
tissue damage [27]. The treatment with PEA attenuates the
degree of peripheral inflammation, reducing oedema and
macrophage infiltration allowing for hypothesizing a syner-
gism between the anti-inflammatory and the neuroprotective
mechanisms of PEA. On the other hand, an inflammation
control mediated by PEA is highlighted also in the spinal
cord. According to previous data CCI induces a COX-2
increase in locations of the central nervous system consistent
with the neuroanatomical substrates of spinal nociception
[28]. COX-2 produces prostaglandins that contribute to the
development and maintenance of spinal hyperexcitability
after peripheral nerve injury [28, 29]. Reducing COX-2 levels,
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Figure 9: CD86 positive cells evaluation in sciatic nerve. 14 days after CCI, 5𝜇m sections of the formalin-fixed distal part of the sciatic nerve
underwent immunohistochemical staining for CD86. Effect of PEA repeated treatments (30mg kg−1 s.c. daily) was evaluated in PPAR-𝛼+/+
and in −/− mice, and representative images are showed, and a detailed image is shown in the insert. Original magnification 20x.
PEA seems able to intervene also in these centralmechanisms
of pain chronicization. To note that a direct inhibition of
pro-inflammatory cytokines, using a TNF-𝛼 antibody, for
instance, attenuates pain-related behavior but has no effect
on nerve regeneration [30].
PEA is a naturally occurring amide between palmitic acid
and ethanolamine it is a lipid messenger known to mimic
several endocannabinoid-driven actions even though PEA
does not bind CB1, CB2, and abn-CBD receptors [31]. So far,
numerous actions of PEA on immune cells such as inhibition
of mast cell degranulation, attenuation of leukocyte extrava-
sation, andmodulation of cytokine release frommacrophages
have been described [16, 32]. Anti-inflammatory effects of
PEA have been associated with peroxisome proliferator-
activated receptor (PPAR)-alpha activation [18]. PPAR-𝛼,
well known for its role in lipid metabolism, controls tran-
scriptional programs involved in the development of inflam-
mation through mechanisms that include direct interactions
with the proinflammatory transcription factors, NF-𝜅B and
AP1, and modulation of IkB function [33]. Pharmacological
studies have demonstrated that PPAR-𝛼 agonists are ther-
apeutically effective in rodent models of inflammatory and
autoimmune diseases [34]. Our results show that in a neuro-
pathic pain model the PPAR-𝛼 genetic ablation determines
a loss of PEA effectiveness in reducing oedema prevention
and CD-86 positive infiltrating cells. On the other hand, the
recruitment of reactive inflammatory cells and subsequent
proinflammatory cascades offers a prime target for neuropro-
tective agents. Agonists of PPAR-𝛼 such as fenofibrate and
Wy-14643 protect against cerebral injury by antioxidant and
anti-inflammatory mechanisms and reduce the incidence of
stroke in mice [35, 36]. Using a spinal cord injury model,
Genovese et al. [37] demonstrated that dexamethasone uti-
lizes PPAR-𝛼 to reduce inflammation and tissue injury in a
rat model of spinal cord trauma. On the contrary, the PPAR-
𝛼 agonist gemfibrozil does not promote tissue preservation
and behavioral recovery after spinal contusion injury in mice
[38]. Our study shows the obligatory role of PPAR-𝛼 for the
neuroprotective effect of PEA in peripheral neuropathy. In
the sciatic nerve of CCI mice PEA exerts a widespread pro-
tective effect on both myelin, and axons throughout a PPAR-
𝛼-mediated mechanism, since PEA treatment fails to rescue
nerve tissue in PPAR-𝛼 knock-out animals. The neuropro-
tective PEA properties were suggested by Skaper et al. [39]
since dose dependently PEA protected cerebellar granule
cells from glutamate toxicity in neuronal single cell cultures
and prevented histamine-induced cell death in hippocampal
cultures. These effects were elicited without involvement of
CB receptors. More recently Koch et al. [40] described the
protective effect of PEA on dentate gyrus granule cells
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Figure 10: COX-2 expression levels in spinal cord. On the 14th day the spinal cord of PPAR-𝛼+/+ and PPAR-𝛼−/− mice was analyzed by
western blot. Upper panel shows the densitometric quantification of COX-2 levels in CCI vehicle-treated animal in comparison with CCI
mice repetitively treated with PEA (30mg kg−1 s.c. daily). Values were normalized to 𝛽-actin immunoreactivity. Data are expressed as the
mean ± SEM of triplicate determinations performed on 5 animals for each group. ∗∗𝑃 < 0.01 was considered as significantly different from
vehicle (+/+).
in excitotoxically lesioned organotypic hippocampal slice
cultures; the specific PPAR-𝛼 antagonist GW6471 blocked
these effects. PEA exerts neuroprotective activities in neu-
rodegenerative diseases. In amousemodel of Alzheimer’s and
Parkinson’s diseases, PEA reduced oxidative and apoptotic
damages and improve behavioral dysfunctions by a PPAR-𝛼-
mediated mechanism [14, 41]. In a cellular model, PEA was
able to blunt 𝛽-amyloid-induced astrocyte activation and,
subsequently, to improve neuronal survival through selective
PPAR-𝛼 activation [42].
In neuropathic conditions PPAR-𝛼 seems to join the anti-
hyperalgesic, anti-inflammatory, and neuroprotective effects
of PEA. On the other hand the inflammatory response to
a damage is crucial for both pain sensation and tissue alte-
rations; the importance of inflammatory mediators is well
demonstrated in the pathogenesis of neuropathic pain, where
infiltrating macrophages and Schwann cells may be involved
in the modulation of these mediators in response to nerve
injury [43].
Starting from the relevance of the PPAR-𝛼 in PEA anti-
neuropathic properties, the misunderstood role of perox-
isome is intriguing. Peroxisomes fulfill multiple tasks in
metabolism and adapt contents and functions according to
cell type, age, and organism. Among the metabolic reac-
tions that take place in peroxisomes, oxygen metabolism,
𝛽-oxidation of a number of carboxylates that cannot be
handled bymitochondria, 𝛼-oxidation of 3-methyl-branched
chain and 2-hydroxy fatty acids, ether lipid synthesis, and
detoxification of glyoxylate are the most important [44,
45]. Patients with peroxisomal dysfunction present with
severe and diverse neurological anomalies, including neu-
ronal migration defects, dysmyelination and inflammatory
demyelination, macrophage infiltration, and axon damage,
proving that these organelles are indispensible for the normal
development and maintenance of the nervous system [45–
47]. Thereafter, the peroxisome stimulation could be a broad
spectrum approach to prevent nervous tissue damage, and
a PEA, PPAR-𝛼-mediated, increase in peroxisome number
and/or functionality could be also hypothesized. A preclinical
study [48] showed that PEA-mediated reduction of spinal
cord damage was paralleled by an induction of PPAR-𝛼
expression and an up-regulation of potential PPAR-𝛼 target
genes, but a clear relationship betweenPPAR-𝛼 activation and
peroxisome boosting is still lacking.
5. Conclusions
The present results demonstrate the neuroprotective proper-
ties of PEA in a preclinical model of neuropathic pain. Anti-
hyperalgesic and neuroprotective properties are related to the
anti-inflammatory effect of PEA and its ability to prevent
Mediators of Inflammation 11
macrophage infiltration in the nerve. PPAR-𝛼 stimulation is
the common pharmacodynamic code.
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